The cost-effectiveness of clozapine. A survey of the literature

Clinical Drug Investigation

Volumn 15, Issue 2, 1998, Pages 137-152

  Morris, Stephen ^a   Hogan, Thomas ^b   McGuire, Alistair ^a  

^a CITY UNIVERSITY   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

CANADA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SWEDEN; UNITED KINGDOM; UNITED STATES;

EID: 0031935216     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199815020-00007     Document Type: Review

References (40)

1. Robins LN, Regier DA. Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: Free Press, 1991
2. Rice DP, Miller LS. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of mental health economics and health policy. Vol. 1. Schizophrenia. Chichester: John Wiley and Sons, 1996
3. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165 Suppl. 25: 18-21
4. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schiziophrenic. Arch Gen Psychiatry 1988; 45: 789-96
5. Kane JM, Freeman HL. Towards more effective antipsychotic treatment. Br J Psychiatry 1994; 165 Suppl. 25: 22-31
6. Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850-4
7. Honigfeld G, Patin J. A two year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990; 41: 882-5
8. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52-6
9. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
10. Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55 Suppl. B: 139-42
11. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160 Suppl. 17: 46-53
12. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992; 160 Suppl. 17: 41-5
13. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994; 55 Suppl. B: 161-5
14. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996; 9: 113-20
15. Essock S. Clozapines cost effectiveness. Am J Psychiatry 1995; 152: 152
16. Frank R. Clozapine's cost-benefit [letter]. Hosp Community Psychiatry 1991; 42: 92
17. Goldman HH. Clozapine's cost-benefit [letter]. Hosp Community Psychiatry 1991; 42: 92-3
18. Rosenheck R, Charney DS, Frisman LK, et al. Clozapines cost-effectiveness. Am J Psychiatry 1995; 152: 152-3
19. Schiller M, Hargreaves WA. Clozapines cost-effectiveness. Am J Psychiatry 1995; 152: 151-2
20. Backhouse ME, Backhouse RJ, Edey SA. Economic evaluation bibliography. Health Econ 1992; 1 Suppl.: 1-236
21. Frankenburg FR, Zanarini MC, Cole JO, et al. Hospitalisation rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 1992; 4: 247-50
22. Meltzer HY, Cola P, Way L, et al. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630-8
23. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38-42
24. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261-4
25. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199-201
26. Essock S, Hargreaves WA, Covell NH, et al. Clozapines effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 323: 683-97
27. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine: a UK clinic-based study. Br J Psychiatry 1997; 171: 125-30
28. Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Technology Overview: Pharmaceuticals, Canadian Coordinating Office for Health Technology Assessment, July 1997
29. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-15
30. Organisation for Economic Co-Operation and Development (OECD). Report on file - OECD economic outlook: 58. Geneva: OECD, 1996
31. Battelle Human Affairs Research Centers. Cost-effectiveness of clozapine for treatment-resistant schizophrenics. Washington. Battelle Human Affairs Research Center, 1989
32. Revicki DA, Luce BR, Weschler JM, et al. Clozapines cost-benefit [reply to letters]. Hosp Community Psychiatry 1991; 42: 93-4
33. Lindstrom LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 1994; 89 Suppl. 380: 74-6
34. Littrel K. Maximizing schizophrenia treatment outcomes: a model for reintegration. Psychiatr Rehab J 1995; 19: 75-7
35. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-90
36. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-7
37. Allebeck P. Schizophrenia: a life-shortening disease. Schizophrenia Bull 1989; 15: 81-9
38. Anderson C, Connelly J, Johnstone EC, et al. Disabilities and circumstances of schizophrenic patients - a follow-up study. Cause of death. Br J Psychiatry 1991; 159 Suppl. 13: 30-3
39. Black DW. Mortality in schizophrenia - the Iowa record-linkage study. Psychosomatics 1988; 29: 55-60
40. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia; a record linkage study. Can J Psychiatry 1991; 36: 239-45